Pro-Calcitonin Levels Following Pediatric Cardiac Surgery
NCT ID: NCT00284570
Last Updated: 2013-11-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
49 participants
OBSERVATIONAL
2006-01-31
2007-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Second, we, the researchers, hope to determine the accuracy of PCT as a marker of infection.
Hypothesis
Our hypothesis is that Procalcitonin is superior to other currently used markers of infection and will prove to be a clinically useful tool for evaluation of infection in children following cardiac surgery.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A new marker of infection, Procalcitonin (PCT), has been found and has been tested in adults and children. PCT has recently been approved by the Food and Drug Administration (FDA) as a marker of infection. PCT has been shown to be a more accurate marker of infection for some groups of patients.
Prior work on a small number of children shows that PCT increases shortly just from heart surgery itself, even without infection. There is little information published about how accurate PCT is for identifying infection in the child heart population. In order to use PCT in our patients, we need to know what the normal levels of PCT are after surgery. Thus, when an infection does happen, we can identify it. We also need to take PCT levels when patients are thought to have infections. We will then need to watch for an infection over the next few days to see if the PCT level rises and can actually predict the presence an infection.
Goals:
1. Determine the Procalcitonin response to cardiopulmonary bypass in children undergoing open-heart surgery. Cardiopulmonary bypass causes a pro-inflammatory state in the patient, and associated rise in Procalcitonin. The ability to use PCT as a marker for infection will require knowledge of its typical response to bypass and the time course to return to baseline.
2. Determine the accuracy of Procalcitonin as a marker of infection, and to compare and contrast these findings with currently used laboratory markers.
Specific Aims
1. Evaluate PCT in the postoperative pediatric cardiac surgical patient as a marker for infection and sepsis.
2. Evaluate PCT's response to cardiopulmonary bypass, and as a predictor of outcome following cardiac surgery.
3. Compare PCT to other markers of inflammation and infection (C-reactive protein and white blood cell response).
By doing this study, we hope to find out two things. First, we hope to find out the PCT response to heart surgery in children by taking blood before surgery and each day for four days after surgery. These blood draws will help us figure out the typical PCT response, the normal increase in PCT after heart surgery, and when the PCT level returns to baseline.
Second, we hope to determine the accuracy of PCT as a marker of infection. Whenever we think a patient may have an infection, it is routine care to take some blood and run lab tests such as a white blood cell count, blood culture, and a C-reactive protein level. Patients in the study will also have an additional 10 drops of blood taken for a PCT level at the same time as the routine blood draw. Even though patients may show signs of an infection, the routine blood test do not always come back positive for an infection. We will compare the routine blood test results (positive or negative for an infection) with the PCT level taken at the same time. If most patients with an infection also have a rise in PCT and those patients without an infection have a normal PCT, then we will prove that PCT is a good, accurate marker for infection in our patients.
This research will help us study infection in our patients. It will help distinguish patients with infection, what the risk factors are, how they are treated, and the response to infection. This information will potentially allow us to use an improved test for identifying infection in a high-risk population of children. Patients in the research project will continue to receive the standard of care treatment after heart surgery and there will be no changes in their care during the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Undergoing cardiopulmonary bypass and cardiac surgery
* Newborn (full term) to up to 6 years of age
Exclusion Criteria
* 6 years of age or older
* Intercurrent illness at time of surgery
* Orthotopic organ transplant recipient
* Pre-operative extra-corporeal support (ECMO)
* Acquired heart disease
5 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Children's Healthcare of Atlanta
OTHER
Emory University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kevin O. Maher, MD
Associate Prefessor of Pediatrics
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kevin Maher, MD
Role: PRINCIPAL_INVESTIGATOR
Emory University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's Healthcare of Atlanta
Atlanta, Georgia, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003 Apr 17;348(16):1546-54. doi: 10.1056/NEJMoa022139.
Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001 Jul;29(7):1303-10. doi: 10.1097/00003246-200107000-00002.
Hauser GJ, Chan MM, Casey WF, Midgley FM, Holbrook PR. Immune dysfunction in children after corrective surgery for congenital heart disease. Crit Care Med. 1991 Jul;19(7):874-81. doi: 10.1097/00003246-199107000-00009.
Jarvis WR, Edwards JR, Culver DH, Hughes JM, Horan T, Emori TG, Banerjee S, Tolson J, Henderson T, Gaynes RP, et al. Nosocomial infection rates in adult and pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System. Am J Med. 1991 Sep 16;91(3B):185S-191S. doi: 10.1016/0002-9343(91)90367-7.
Mayhall CG. Diagnosis and management of infections of implantable devices used for prolonged venous access. Curr Clin Top Infect Dis. 1992;12:83-110. No abstract available.
Galetto-Lacour A, Zamora SA, Gervaix A. Bedside procalcitonin and C-reactive protein tests in children with fever without localizing signs of infection seen in a referral center. Pediatrics. 2003 Nov;112(5):1054-60. doi: 10.1542/peds.112.5.1054.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB00002022
Identifier Type: -
Identifier Source: org_study_id